Services · Software Validation

Cutting Validation Costs with CSA and AI-Assisted Documentation

Time-consuming CSV projects are tying up your IT resources and straining budgets, often without any measurable improvement in actual testing quality. Computer Software Assurance (CSA) shifts effort from documentation to risk-based testing, and AI support speeds up the documents that remain. How large the saving is in a given case is set out per system portfolio.

Our services for CSA and AI-assisted validation

Automated Test Protocol Generation
AI prepares properly formatted test protocols from requirements and test results. Qualified personnel review and approve the content; the project-specific potential lies in document creation.
Validation Plan and Report from Templates
AI populates predefined regulatory templates with project-specific content: consistent, complete and in a regulatorily accepted structure.
Automatic Traceability
Requirement: test case: result linkages are maintained automatically. No manual reconciliation, no risk of gaps in traceability.
Efficient Change Control
For system updates, AI assesses the regulatory impact and generates an impact assessment report. Re-validation scope is reduced to what is risk-justified.
Accelerated Vendor Assessment
AI-assisted analysis of manufacturer documentation (test reports, certificates, SDLC evidence) identifies validation-relevant information precisely, no more hours of manual reading.

Clarify scope?

Book an intro call

CSA-Wegweiser

Welche Ausgangslage beschreibt Ihr System?

Wählen Sie die Ausgangslage. Sie erhalten einen fokussierten Startpunkt mit passenden Vertiefungen und einem direkten Kontaktweg.

Einführung mit CSA-Ansatz

Wir bewerten GxP-Kritikalität, nutzen Herstellernachweise und fokussieren Tests auf geschäftskritische Funktionen.

Traditional Computer System Validation (CSV) has been the regulatory standard for IT systems in the pharmaceutical industry for decades. The V-model is proven, but the documentation-intensive nature of the classic approach has a price: in practice a substantial share of project costs falls on document creation and review, not on actual testing.

Our approach in GxP projects: from planning through release – each step delivers evidence you can present in QA review and audit. View GxP consulting in five steps

The Problem: CSV as a Cost Driver

Traditional Computer System Validation (CSV) has been the regulatory standard for IT systems in the pharmaceutical industry for decades. The V-model is proven, but the documentation-intensive nature of the classic approach has a price: in practice a substantial share of project costs falls on document creation and review, not on actual testing.

The result: Systems are introduced more slowly, resources are tied up in paperwork and IT projects are hampered by validation overhead. Meanwhile, the regulators are clear: what matters is proof of system quality, not the page count of the documentation.

Classic CSV
Documentation-Oriented
  • Full specification hierarchy (URS, FS, DS)
  • Formal protocols for IQ, OQ, PQ
  • Extensive vendor documentation
  • Validation report + release process
  • Re-validation for every update
  • High review and sign-off burden
CSA + AI (Modern Approach)
Testing-Centric & Efficient
  • Risk-based document scope
  • Test depth proportional to GxP criticality
  • AI generates documents from requirements
  • Vendor evidence reduces own effort
  • Lean change control management
  • Focus on actual quality evidence

What Is Computer Software Assurance (CSA)?

In September 2022, the FDA published the final guidance "Computer Software Assurance for Production and Quality System Software". CSA is not a replacement for CSV, but a modern framework for a risk-based, efficiency-oriented implementation. The key difference: less documentation overhead, more focus on actual testing activities.

CSA classifies systems into two categories: Category A (lower GxP criticality, simplified assurance) and Category B (high GxP criticality, comprehensive assurance). This differentiation aligns test depth with risk and can avoid unnecessary documentation for supporting systems.

How AI Amplifies the Cost Reduction

The CSA approach reduces the required document scope, and AI speeds up the creation of the documents that remain. The actual saving depends on the system portfolio and is stated per system in the proposal, not promised as a blanket figure.

CSA
risk-based test depth instead of blanket scripted documentation
GAMP 5
compatible: categories stay, test depth follows the risk
FDA
Guidance Sept. 2022: official regulatory framework

Our CSA + AI Implementation Process

1
Portfolio Analysis & System Classification
Inventory of all GxP-relevant systems. Classification into CSA Category A or B based on a structured risk analysis. Quantification of savings potential per system.
2
CSA Framework Setup
Implementation of a CSA-compliant validation framework: adapted SOPs, templates and process guidelines based on FDA Guidance 2022.
3
AI Tool Integration
Integration of AI-driven document generation into your validation workflow. Training of QA and IT teams in the efficient use of AI-generated validation documents.
4
Pilot Project
Execution of a first complete validation project under the new methodology. Measurement of actual cost savings and identification of further optimisation potential.
5
Rollout & Continuous Optimisation
Extension of the new methodology to all GxP validation projects. Regular process efficiency reviews and adaptation to regulatory developments.

FAQ: Cutting Validation Costs with CSA & AI

Does CSA apply under EU-GMP Annex 11?
CSA is formally an FDA guidance. EU-GMP Annex 11 is principle-based and permits risk-based approaches without prescribing a specific methodology. Many European organisations are successfully applying CSA principles within their Annex 11 framework, particularly for dual submissions (FDA + EMA) or as best practice. An individual regulatory assessment is always recommended.
Do already-validated systems need to be converted to CSA?
No. Existing validated systems remain valid. CSA is appropriate for new systems, upcoming re-validations or as a strategic decision for the entire validation organisation. A phased transition is fully regulatorily accepted.
What is the realistic savings potential for our organisation?
The savings potential depends on your current validation practice, the system portfolio and the distribution between Category A and Category B systems. cube one conducts a savings potential analysis as part of an initial audit and states the result per system rather than quoting a blanket percentage.
Is AI-generated documentation safe during an FDA inspection?
Yes, provided processes are correctly documented and responsibilities are clear. What matters is not the creation tool, but the content quality and documented release by qualified personnel. cube one ensures that all AI-generated documents are fully reviewable and signable, with a clear change history trail.

Reduce Validation Costs, Maintain Compliance

We assess where CSA and AI can reduce your documentation effort without reducing the required depth of evidence.

Analyse Your Savings Potential